AbbVie ABBV Global ranking
https://en.wikipedia.org/wiki/AbbVie
AbbVie Inc. is a pharmaceutical company headquartered in North Chicago, Illinois. It is ranked 6th on the list of largest biomedical companies by revenue. The company's primary product is Humira (adalimumab) ($21 billion in 2022 revenues, 37% of total), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohn's disease, plaque psoriasis, and ulcerative colitis.
It also developed Skyrizi ($5 billion in 2022 revenues), an interleukin-23 (IL-23) inhibitor also used to treat autoimmune diseases. Its other major products include Botox ($5 billion in 2022 revenues), Imbruvica to treat cancer ($4.5 billion in 2022 revenues), Rinvoq to treat arthritis ($2.5 billion in 2022 revenues), Venclexta to treat leukemia and lymphoma ($2 billion in annual revenues), Vraylar to treat schizophrenia and bipolar disorder ($2 billion in 2022 revenues), and Mavyret to treat Hepatitis C ($1.5 billion in 2022 revenues).[1] The company is also committed to product development for other treatments of cancer, neurologic diseases, eye care, and cystic fibrosis.[1][2]
In 2023, Humira began facing competition from a biosimilar developed by Amgen. The company is also developing a drug for Parkinson's disease that could be a blockbuster drug in 2027 and is awaiting approval from the Food and Drug Administration for epcoritamab, a blood-cancer therapy under development in partnership with Genmab.[3]
The name "AbbVie" is derived from a combination of "Abbott", the name of its former parent company, with "vie," intended as a reference to a Latin root meaning "life."[4]
Komentarze
Prześlij komentarz